DT
Dewpoint Therapeutics, Inc.
SEC filingBiotechnology · Boston, MA
Amount raised$77.2Msold at filing
Total offering$82.3M$5.1M still open
Investors in the raise23count reported to the SEC
FiledJul 13, 2026first sale Sep 9, 2025
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Isaac A. Klein, M.D., Ph.D.Executive Officer
Regina Barzilay, Ph.D.Director
Steven H. Neier, Ph.D.Director
Ameet Nathwani, M.D.Executive Officer, Director
Giuseppe A. Ciaramella, Ph.D.Director
Mark A. Murcko, Ph.D.Director
Srinivas Akkaraju, M.D., Ph.D.Director
Olivier Brandicourt, M.D.Director
Anthony A. Hyman, Ph.D.Director
Amir H. Nashat, Sc.D.Director
Richard A. Young, Ph.D.Director
Executive officers, directors and promoters as listed on the Form D.